NZ598712A - Methods and compositions for diagnosis and prognosis of renal injury and renal failure - Google Patents

Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Info

Publication number
NZ598712A
NZ598712A NZ598712A NZ59871210A NZ598712A NZ 598712 A NZ598712 A NZ 598712A NZ 598712 A NZ598712 A NZ 598712A NZ 59871210 A NZ59871210 A NZ 59871210A NZ 598712 A NZ598712 A NZ 598712A
Authority
NZ
New Zealand
Prior art keywords
apolipoprotein
renal
prognosis
diagnosis
compositions
Prior art date
Application number
NZ598712A
Other languages
English (en)
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Priority to NZ624609A priority Critical patent/NZ624609A/en
Publication of NZ598712A publication Critical patent/NZ598712A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NZ598712A 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure NZ598712A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ624609A NZ624609A (en) 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US23812809P 2009-08-28 2009-08-28
US23812709P 2009-08-28 2009-08-28
US23812109P 2009-08-28 2009-08-28
US23812009P 2009-08-28 2009-08-28
US23813409P 2009-08-28 2009-08-28
US23811509P 2009-08-28 2009-08-28
US23812509P 2009-08-28 2009-08-28
US23812909P 2009-08-28 2009-08-28
US23811809P 2009-08-28 2009-08-28
US23812309P 2009-08-28 2009-08-28
US24400209P 2009-09-18 2009-09-18
US24399709P 2009-09-18 2009-09-18
US24399109P 2009-09-18 2009-09-18
US24399309P 2009-09-18 2009-09-18
PCT/US2010/046910 WO2011025917A1 (en) 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (1)

Publication Number Publication Date
NZ598712A true NZ598712A (en) 2014-05-30

Family

ID=43628398

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ598712A NZ598712A (en) 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ624609A NZ624609A (en) 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ624609A NZ624609A (en) 2009-08-28 2010-08-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Country Status (9)

Country Link
US (2) US20120315649A1 (https=)
EP (3) EP2470905B1 (https=)
JP (2) JP5775874B2 (https=)
CN (2) CN104483488A (https=)
AU (1) AU2010286559B2 (https=)
CA (1) CA2772336A1 (https=)
HK (1) HK1208074A1 (https=)
NZ (2) NZ598712A (https=)
WO (1) WO2011025917A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075744A1 (en) 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011213684B2 (en) 2010-02-05 2014-11-20 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) * 2010-06-23 2015-05-29 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
IN2012MN02812A (https=) 2010-06-23 2015-05-22 Astute Medical Inc
US10557856B2 (en) 2010-09-24 2020-02-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers of renal injury
EP3761034A3 (en) * 2011-01-26 2021-02-17 University of Pittsburgh - Of the Commonwealth System of Higher Education Urine biomarkers for prediction of recovery after acute kidney injury: proteomics
EP2503340A1 (en) * 2011-03-22 2012-09-26 Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada Diagnostic marker for relapsing primary idiopathic focal segmental glomerulosclerosis
TW201250248A (en) * 2011-04-25 2012-12-16 Kyowa Medex Co Ltd Prognostication method of renal failure
US20150168422A1 (en) * 2011-05-12 2015-06-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
EP3699591A1 (en) * 2012-04-02 2020-08-26 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
EP3361255B1 (en) 2013-01-17 2020-03-11 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104569417B (zh) * 2013-10-12 2016-06-01 广州瑞博奥生物科技有限公司 一种用于早期诊断急性肾损伤的抗体芯片试剂盒
CN110007084B (zh) 2013-12-03 2022-11-18 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN107735147A (zh) * 2015-05-12 2018-02-23 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
KR20210019459A (ko) * 2018-05-24 2021-02-22 레니버스 테라퓨틱스, 인크. 신장 손상 및 신부전 위험이 있는 환자를 치료하는 방법
CN117825674A (zh) * 2023-12-28 2024-04-05 南方医科大学南方医院 用于评估肝病预后的分子标志物及诊断试剂盒
CN121186383B (zh) * 2025-11-24 2026-03-13 华中科技大学 慢性肾病的蛋白质标志物的筛选及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
ATE376187T1 (de) * 1998-12-21 2007-11-15 Univ Monash Nachweis von erkrankungen der nieren und behandlung
WO2002048329A2 (en) * 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
WO2002081515A1 (fr) * 2001-04-03 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Proteine de liaison de facteur de croissance de type insuline
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
MXPA05010385A (es) * 2003-03-27 2006-03-08 Childrens Hosp Medical Center Metodo y estuche para detectar el inicio temprano de lesion celular tubular renal.
CN1791797A (zh) * 2003-03-27 2006-06-21 儿童医院医疗中心 用于检测肾小管细胞损伤的早发的方法和试剂盒
US7416854B2 (en) * 2004-01-22 2008-08-26 Promega Corporation Luminogenic and nonluminogenic multiplex assay
US20090215046A1 (en) * 2004-01-27 2009-08-27 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays methods of use thereof for diagnosis of colon cancer
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
AU2005288522B2 (en) * 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
US7141382B1 (en) * 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
PL1831699T3 (pl) * 2004-12-20 2010-04-30 Antibodyshop As Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek
WO2006102979A2 (de) * 2005-03-31 2006-10-05 Johannes Gutenberg-Universität Mainz Entzündungsmarker und kombinationen davon als biochemische marker bei kardiovaskulären erkrankungen
US20060253262A1 (en) * 2005-04-27 2006-11-09 Emiliem Novel Methods and Devices for Evaluating Poisons
TW200716764A (en) * 2005-05-02 2007-05-01 Genenews Inc Bladder cancer biomarkers and uses thereof
JP4800384B2 (ja) * 2005-06-08 2011-10-26 ヒタチ ケミカル リサーチ センター インコーポレイテッド 腫瘍細胞及び刺激された白血球におけるｍＲＮＡの発現プロファイルに基づく腫瘍性疾患に対する免疫応答を予測する方法
US7662578B2 (en) 2006-04-21 2010-02-16 Children's Hospital Medical Center Method and kit for the early detection of impaired renal status
DE602007007595D1 (en) * 2006-04-24 2010-08-19 Univ Wien Med Ten
JP2010517023A (ja) * 2007-01-25 2010-05-20 エフ．ホフマン−ラ ロシュ アーゲー 心不全の評価におけるｉｇｆｂｐ−７の使用
WO2008122670A2 (en) * 2007-04-10 2008-10-16 Integragen Human diabetes susceptibility tnfrsf10b gene
US20110183434A1 (en) * 2008-01-17 2011-07-28 Myles Wolf Diagnostic methods and kits using fibroblast growth factor-23
CA2740923A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
JP2015212704A (ja) 2015-11-26
EP2470905A1 (en) 2012-07-04
JP5775874B2 (ja) 2015-09-09
CN104483488A (zh) 2015-04-01
CN102792161B (zh) 2014-11-12
JP6054481B2 (ja) 2016-12-27
EP3151005A1 (en) 2017-04-05
HK1208074A1 (en) 2016-02-19
US20150204892A1 (en) 2015-07-23
CN102792161A (zh) 2012-11-21
JP2013503344A (ja) 2013-01-31
HK1172691A1 (en) 2013-04-26
EP2470905B1 (en) 2015-01-07
EP2894473A1 (en) 2015-07-15
CA2772336A1 (en) 2011-03-03
NZ624609A (en) 2015-12-24
EP2470905A4 (en) 2013-08-14
EP2894473B1 (en) 2016-09-21
AU2010286559A1 (en) 2012-04-05
US20120315649A1 (en) 2012-12-13
WO2011025917A1 (en) 2011-03-03
AU2010286559B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
NZ598712A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ705411A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594771A (en) Methods and compositions for diagnosis and prognosis of renal injury and failure
NZ628843A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ600160A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ606124A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ591437A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ700695A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ594772A (en) Diagnosis and prognosis of renal injury and renal failure using vitamin k dependent protein c
NZ605698A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ608384A (en) Biomarkers of renal injury
NZ604873A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ619918A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ630621A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ628085A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2721907T3 (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3734280A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ615010A (en) Detection of sleep onset
WO2013113012A3 (en) Methods for profiling and quantitating cell-free rna
NZ598741A (en) Methods and composition for diagnosis and prognosis of renal injury and renal failure by performing assays to detect metalloproteinase inhibitor 4 on a body fluid sample
WO2014004889A3 (en) Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
EP1989551A4 (en) METHOD OF DETECTING OR DIAGNOSING NEURODEGENERATIVE DISEASE OR DISEASE

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 AUG 2017 BY FB RICE

Effective date: 20140902

LAPS Patent lapsed